Solstein Capital’s Zimmer Biomet ZBH Stock Holding History

Solstein Capital’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,769	Closed	-$402K	–	403
2019 Q4	$402K	Buy	+2,769	New	+$382K	0.81%	34

Other funds holding ZBH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Solstein Capital's ZBH Position: Q1 2020 in Review

Solstein Capital sold out of Zimmer Biomet (ZBH) in Q1 2020, closing a stake of 2,769 shares — an estimated $402K sold.

Solstein Capital first reported a position in ZBH in Q4 2019 and held it in 1 quarter. The position peaked at $402K in Q4 2019. 883 funds tracked by Wall St. Rank hold ZBH as of Q1 2020.

Solstein Capital reported no remaining Zimmer Biomet position as of Q1 2020 after selling out during the quarter.
Solstein Capital sold 2,769 Zimmer Biomet shares in Q1 2020, an estimated $402K.
Solstein Capital first reported a position in Zimmer Biomet in Q4 2019 and held it in 1 quarter.
Solstein Capital's Zimmer Biomet position peaked at $402K in Q4 2019.
883 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2020.

Based on Solstein Capital's 13F filing for Q1 2020, filed 12 May 2020.